目的 分析恒古骨伤愈合剂联合注射用骨肽治疗胫骨平台骨折的临床研究。方法 选取2019年6月—2022年6月郑州市第七人民医院治疗的143例胫骨平台骨折患者，按照随机数字表法将患者分为对照组（72例）和治疗组（71例）。对照组患者在手术后静脉滴注注射用骨肽，100 mg注射用骨肽加入0.9%氯化钠注射液250 mL中，1次/d。治疗组在对照组的治疗基础上口服恒古骨伤愈合剂，25 mL/次，隔日用药一次。两组治疗时间为1个月。观察两组的临床疗效，比较临床症状改善时间、血清创伤指标和骨代谢指标。结果 治疗后，治疗组患者膝关节恢复优良率是90.14%，显著高于对照组的76.39%（P＜0.05）。治疗后，治疗组患者疼痛消失时间、下床活动时间、骨折愈合时间均显著短于对照组（P＜0.05）。治疗后，两组患者白细胞介素-10（IL-10）、白细胞介素-1（IL-1）和C反应蛋白（CRP）均较治疗前增加（P＜0.05），且治疗后治疗组IL-10、IL-1和CRP明显低于对照组（P＜0.05）。治疗后，两组骨保护素（OPG）、骨形态发生蛋白2（BMP-2）水平均较治疗前显著升高，而Ⅰ型胶原羧基末端肽（CTX-Ⅰ）水平均显著下降（P＜0.05）；治疗后，治疗组患者骨代谢指标改善优于对照组（P＜0.05）。水平。结论 恒古骨伤愈合剂联合注射用骨肽治疗胫骨平台骨折具有较好的临床疗效，有助于更快改善临床症状，减轻炎症反应，改善骨代谢水平，促进膝关节功能恢复。

Objective To investigate the therapeutic effect of Henggu Gushang Yuheji combined with Ossotide for injection in treatment of tibial plateau fracture. Methods A total of 143 patients with tibial plateau fracture treated in Zhengzhou Seventh People’s Hospital from June 2019 to June 2022 were selected and divided into control group (72 cases) and treatment group (71 cases) according to random number table method. Patients in the control group were iv administered with Ossotide for injection after surgery, 100 mg Ossotide for injection was added to 0.9% sodium chloride injection 250 mL, once daily. Patients in the treatment group were po administered with Henggu Gushang Yuheji, 25 mL/time, once every other day. The treatment time of the two groups was 1 month. The clinical efficacy of the two groups was observed, and the improvement time of clinical symptoms, serum trauma indexes and bone metabolism indexes were compared. Results After treatment, the recovery rate of knee joint in the treatment group was 90.14%, which was significantly higher than that in the control group (76.39%, P < 0.05). After treatment, the time of pain disappearance, the time of getting out of bed, and the time of fracture healing in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, interleukin-10 (IL-10), interleukin-1 (IL-1) and C-reactive protein (CRP) were increased in both groups compared with before treatment (P < 0.05), and after treatment, IL-10, IL-1 and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of osteoprotectin (OPG) and bone morphogenetic protein 2 (BMP-2) were significantly increased in both groups compared with before treatment, but the levels of carboxyl terminal peptide of type Ⅰ collagen (CTX-Ⅰ) were significantly decreased in both groups (P < 0.05). After treatment, the improvement of bone metabolism indexes in treatment group was better than that in control group (P < 0.05). Conclusion Henggu Gushang Yuheji combined with Ossotide for injection has good clinical effect in treatment of tibial plateau fracture, and is helpful to improve clinical symptoms faster, reduce inflammation, improve bone metabolism and promote the recovery of knee function.

R982

河南省中医药科学研究专项课题（2022JDZX123）